PE2499A1 - Composiciones con recubrimientos que controlan la liberacion - Google Patents
Composiciones con recubrimientos que controlan la liberacionInfo
- Publication number
- PE2499A1 PE2499A1 PE1997000805A PE00080597A PE2499A1 PE 2499 A1 PE2499 A1 PE 2499A1 PE 1997000805 A PE1997000805 A PE 1997000805A PE 00080597 A PE00080597 A PE 00080597A PE 2499 A1 PE2499 A1 PE 2499A1
- Authority
- PE
- Peru
- Prior art keywords
- active substance
- dihydrogenocitrate
- matrix
- sodium
- subject
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
CARACTERIZADAS PORQUE COMPRENDEN COMO PRINCIPIO ACTIVO EL MONOHIDROCLORURO DE [R-(Z)]-O-(METOXIIMINO)-O-(1-AZABICICLO[2.2.2]OCT-3-IL) ACETONITRILO; Y TRATANDOSE DE (1) UN COMPRIMIDO QUE INCLUYE UNA MATRIZ, QUE COMPRENDE: DE 0,005 mg A 0,1 mg DEL PRINCIPIO ACTIVO; 75 mg DE HIDROXIPROPILMETILCELULOSA E4M CR; 3 mg DE DIHIDROGENOCITRATO DE SODIO; 70,38 mg DE LACTOSA, FAST FLO; 1,5 mg DE ESTEARATO DE MAGNESIO; 2,25 mg DE OPADRY WHITE; Y (2) GRANULOS O ESFERAS PARA PREPARAR CAPSULAS, QUE COMPRENDE: DE 0,003% P/P A 0,06% P/P (CALCULADO COMO BASE LIBRE) DEL PRINCIPIO ACTIVO; 3% P/P DE OPADRY CLEAR; 1,5% P/P DE DIHIDROGENOCITRATO DE SODIO; AMBAS COMPOSICIONES SE SOMETEN A RECUBRIMIENTOS: PRIMERO DE SELLADO, QUE CONSISTE EN OPADRY CLEAR (YS-1-9025A) AL 10 % DE SOLIDOS, EN AGUA; SEGUNDO, RECUBRIMIENTO POLIMERICO, QUE CONSISTE DE ETILCELULOSA (SURELEASE) AL 25 % DE SOLIDOS, EN AGUA; Y FINALMENTE UN TERCER RECUBRIMIENTO DE SELLADO; LA COMPOSICION QUE INCLUYE MATRIZ, SE SOMETE A UN CUARTO RECUBRIMIENTO POLIMERICO. ESTAS COMPOSICIONES LIBERAN EL PRINCIPIO ACTIVO EN EL TRACTO DIGESTIVO DURANTE 8 A 12 HORAS DESPUES DE LA INGESTION; DICHO PRINCIPIO ACTIVO ACTUA MEJORANDO EL PROCESADO DE LA PROTEINA PRECURSORA AMILOIDE POR UNA VIA AMILOIDOGENICA, SIENDO UTIL EN LA PREVENCION Y TRATAMIENTO DE LA DEMENCIA Y LA ENFERMEDAD DE ALZHEIMER
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9619074.9A GB9619074D0 (en) | 1996-09-12 | 1996-09-12 | Composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE2499A1 true PE2499A1 (es) | 1999-03-24 |
Family
ID=10799833
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1997000805A PE2499A1 (es) | 1996-09-12 | 1997-09-10 | Composiciones con recubrimientos que controlan la liberacion |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP0929301A2 (es) |
| JP (1) | JP2001500150A (es) |
| KR (1) | KR20000036039A (es) |
| CN (2) | CN1235544A (es) |
| AR (1) | AR008176A1 (es) |
| AU (1) | AU724086B2 (es) |
| BR (1) | BR9711734A (es) |
| CA (1) | CA2265661A1 (es) |
| CO (1) | CO5031291A1 (es) |
| CZ (1) | CZ83299A3 (es) |
| GB (1) | GB9619074D0 (es) |
| HU (1) | HUP9904401A3 (es) |
| ID (1) | ID19589A (es) |
| IL (1) | IL128781A0 (es) |
| MA (1) | MA24359A1 (es) |
| NO (1) | NO991194D0 (es) |
| NZ (1) | NZ334268A (es) |
| PE (1) | PE2499A1 (es) |
| PL (1) | PL332074A1 (es) |
| TR (1) | TR199900505T2 (es) |
| WO (1) | WO1998010762A2 (es) |
| ZA (1) | ZA978133B (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2775597B1 (fr) * | 1998-03-04 | 2001-04-20 | Gattefosse Ets Sa | Pellet administrable par voie orale apte a ameliorer la biodisponibilite de la substance active, procede de fabrication |
| CN1292696A (zh) * | 1998-03-11 | 2001-04-25 | 史密丝克莱恩比彻姆有限公司 | 组合物 |
| DE19918325A1 (de) * | 1999-04-22 | 2000-10-26 | Euro Celtique Sa | Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion |
| FR2796840B1 (fr) * | 1999-07-26 | 2003-06-20 | Ethypharm Lab Prod Ethiques | Comprimes faiblement doses et procede de preparation |
| US6733781B2 (en) | 2000-12-06 | 2004-05-11 | Wyeth | Fast dissolving tablet |
| AR040682A1 (es) | 2002-07-25 | 2005-04-13 | Pharmacia Corp | Forma de dosificacion una vez al dia de pramipexol |
| KR101139744B1 (ko) * | 2003-04-25 | 2012-04-26 | 미쓰비시 타나베 파마 코퍼레이션 | 알킬렌 디옥시벤젠 유도체 함유 경구 투여용 조성물 |
| EP1628642B2 (en) * | 2003-05-14 | 2013-01-23 | Aptalis Pharma Limited | Controlled drug release composition resistant to in vivo mechanic stress |
| US20050142191A1 (en) * | 2003-06-23 | 2005-06-30 | Neurochem (International) Limited | Pharmaceutical formulations of amyloid inhibiting compounds |
| JP2005272347A (ja) * | 2004-03-24 | 2005-10-06 | Ohara Yakuhin Kogyo Kk | 固形製剤の製造方法 |
| EP2135602A1 (en) | 2004-08-13 | 2009-12-23 | Boehringer Ingelheim International GmbH | Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof |
| SG164375A1 (en) | 2004-08-13 | 2010-09-29 | Boehringer Ingelheim Int | Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof |
| EP1970056A1 (en) * | 2007-03-15 | 2008-09-17 | Polichem S.A. | Time-specific delayed/pulsatile release dosage forms |
| US9132096B1 (en) | 2014-09-12 | 2015-09-15 | Alkermes Pharma Ireland Limited | Abuse resistant pharmaceutical compositions |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69034146T2 (de) * | 1989-04-13 | 2005-07-14 | Beecham Group P.L.C., Brentford | Chemische Verbindungen |
| GB9409718D0 (en) * | 1994-05-14 | 1994-07-06 | Smithkline Beecham Plc | Novel compounds |
| GB9421472D0 (en) * | 1994-10-25 | 1994-12-07 | Smithkline Beecham Plc | Novel methods |
| AR004178A1 (es) * | 1995-07-29 | 1998-11-04 | Smithkline Beecham Plc | Procedimiento para la formulacion de un farmaco, una composicion farmaceutica obtenible mediante este procedimiento y el uso de la misma. |
-
1996
- 1996-09-12 GB GBGB9619074.9A patent/GB9619074D0/en active Pending
-
1997
- 1997-09-08 WO PCT/GB1997/002418 patent/WO1998010762A2/en not_active Application Discontinuation
- 1997-09-08 EP EP97939064A patent/EP0929301A2/en not_active Withdrawn
- 1997-09-08 PL PL97332074A patent/PL332074A1/xx unknown
- 1997-09-08 IL IL12878197A patent/IL128781A0/xx unknown
- 1997-09-08 JP JP10513352A patent/JP2001500150A/ja active Pending
- 1997-09-08 AU AU41288/97A patent/AU724086B2/en not_active Ceased
- 1997-09-08 CA CA002265661A patent/CA2265661A1/en not_active Abandoned
- 1997-09-08 NZ NZ334268A patent/NZ334268A/xx unknown
- 1997-09-08 TR TR1999/00505T patent/TR199900505T2/xx unknown
- 1997-09-08 BR BR9711734A patent/BR9711734A/pt unknown
- 1997-09-08 HU HU9904401A patent/HUP9904401A3/hu unknown
- 1997-09-08 KR KR1019997002030A patent/KR20000036039A/ko not_active Application Discontinuation
- 1997-09-08 CZ CZ99832A patent/CZ83299A3/cs unknown
- 1997-09-08 CN CN97199411A patent/CN1235544A/zh active Pending
- 1997-09-09 CO CO97052280A patent/CO5031291A1/es unknown
- 1997-09-10 PE PE1997000805A patent/PE2499A1/es not_active Application Discontinuation
- 1997-09-10 ID IDP973137A patent/ID19589A/id unknown
- 1997-09-10 AR ARP970104130A patent/AR008176A1/es not_active Application Discontinuation
- 1997-09-10 ZA ZA978133A patent/ZA978133B/xx unknown
- 1997-09-10 MA MA24792A patent/MA24359A1/fr unknown
-
1999
- 1999-03-11 NO NO991194A patent/NO991194D0/no unknown
-
2003
- 2003-01-23 CN CN03102977A patent/CN1446535A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP0929301A2 (en) | 1999-07-21 |
| AU4128897A (en) | 1998-04-02 |
| CA2265661A1 (en) | 1998-03-19 |
| AR008176A1 (es) | 1999-12-09 |
| AU724086B2 (en) | 2000-09-14 |
| CN1235544A (zh) | 1999-11-17 |
| GB9619074D0 (en) | 1996-10-23 |
| CZ83299A3 (cs) | 1999-08-11 |
| NO991194L (no) | 1999-03-11 |
| JP2001500150A (ja) | 2001-01-09 |
| PL332074A1 (en) | 1999-08-30 |
| BR9711734A (pt) | 1999-08-24 |
| CN1446535A (zh) | 2003-10-08 |
| NZ334268A (en) | 2000-10-27 |
| WO1998010762A2 (en) | 1998-03-19 |
| KR20000036039A (ko) | 2000-06-26 |
| ZA978133B (en) | 1999-04-12 |
| TR199900505T2 (es) | 1999-06-21 |
| WO1998010762A3 (en) | 1998-06-04 |
| CO5031291A1 (es) | 2001-04-27 |
| HUP9904401A2 (hu) | 2000-06-28 |
| IL128781A0 (en) | 2000-01-31 |
| HUP9904401A3 (en) | 2001-03-28 |
| ID19589A (id) | 1998-07-23 |
| NO991194D0 (no) | 1999-03-11 |
| MA24359A1 (fr) | 1998-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE2499A1 (es) | Composiciones con recubrimientos que controlan la liberacion | |
| EP0248447B1 (en) | Sustained release formulations | |
| US6177102B1 (en) | Once daily analgesic tablet | |
| EP1021171B1 (en) | Delayed total release gastrointestinal drug delivery system | |
| US7485322B2 (en) | Modified release pharmaceutical composition | |
| FI88675B (fi) | Elastiska filmoeverdrag och deras anvaendning | |
| Bernkop-Schnurch et al. | Multifunctional matrices for oral peptide delivery | |
| US5750145A (en) | Stable gelatin coated aspirin tablets | |
| CA2170748A1 (en) | Pharmaceutical preparations for the targeted treatment of crohn's disease and ulcerative colitis | |
| IL118240A (en) | Oral coated capsule dosage form of omega-3 polyunsaturated acid for release of the acid in the intestine | |
| UA72483C2 (en) | Moxifloxacin-containing pharmaceutical preparation and method for its manufacture | |
| CA2251987A1 (en) | Microparticles | |
| TW200602085A (en) | Controlled-release pharmaceutical composition and method for producing same | |
| OA10377A (en) | Polymer coated tablet comprising amoxycillin and clavulanate | |
| CN1112417A (zh) | 药物组合物 | |
| BR9913696A (pt) | Sistema de liberação de drogas, administrado oralmente, proporcionando controle temporal e espacial | |
| HUP9900800A2 (hu) | Szerves vegyületeket tartalmazó készítmények | |
| ES2245071T3 (es) | Procedimiento para obtener una preparacion de tramadol retardada con un perfil de liberacion estable en almacenamiento sin necesidad de tratar termicamente el producto revestido. | |
| CA2229283A1 (en) | Prednisolone metasulphobenzoate preparation for the treatment of inflammatory bowel disease | |
| IE58621B1 (en) | Pancreatic enzyme products and a process for the preparation thereof | |
| CA2219777A1 (en) | Nanoparticles for oral administration of pharmaceutical agents of low solubility | |
| CA2055905A1 (en) | Pharmaceutical composition comprising calcium polycarbophil | |
| BR0212155A (pt) | Composição farmacêutica | |
| ES2184452T3 (es) | Preparacion farmaceutica que contiene levotiroxina de sodio. | |
| US5958873A (en) | Oral formulation for treatment of bacteria-induced diseases of the colon |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |